Anti-tumor Study of DNA-RNA Nanocarriers Linked to AS 1411 Aptamer
Chang-Qi Zhao,Ke-Li Ge,Zi-Han Jia,Jia-Yao Bai,Jin-Yu Zhang,Yin-Lin Ge
DOI: https://doi.org/10.16476/j.pibb.2022.0278
2023-01-01
PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS
Abstract:<bold>Objective</bold> To study the effectiveness of DNA-RNA molecules linked with aptamers as hybrid vectors to target tumor cells and introduce functional RNA molecules into cells, as well as their effects on tumor cells.<bold>Methods</bold> Design and synthesize short complementary DNA and RNA molecules, and assemble them into DNA-RNA hybrid chains; connect AS1411 aptamer as targeting molecule, and then connect p21 saRNA and TIGIT siRNA as drug molecules, denoted as P21 saRNA and TIGIT siRNA , constitute a hybrid vector, the general structural formula is AS1411-DNA/RNA-sxRNA; detect whether AS1411-DNA/RNA-sxRNA can target and enter tumor cells and its effect on the survival, migration, invasion and apoptosis of tumor cells.<bold>Results</bold> Equimolar parts of the designed hybrid vector were added to the hybridization buffer system and incubated at a specific temperature. TBM polyacrylamide gel electrophoresis detected the successful assembly of AS1411-DNA/RNA-sxRNA; AS1411-DNA/RNA-sxRNA hybridized carriers are also showed good anti-degradation stability under the condition of 10% serum; observed under fluorescence microscope and laser confocal microscope, there were a large number of green fluorescent signals on the surface and in the cell of SKOV3 cells, and the hybrid carrier successfully entered the tumor cells. After the hybrid carrier incubated, at the mRNA level, the expression of p21 gene (2.14 +/- 0.25) was nearly 2 times that of the control group (1.02 +/- 0.10), P<0.05, the expression of TIGIT gene (0.63 +/- 0.09) was lower than that of the control group (1.09 +/- 0.15), P<0.05, at the protein level, the expression of p21 gene (1.57 +/- 0.16) was more than 1.5 times that of the control group (1.10 +/- 0.09), P<0.05, the expression of TIGIT gene (0.61 +/- 0.12) was lower than that of the control group (1.01 +/- 0.07) , P<0.05. The CCK-8 experiment showed that the proliferation ability of ovarian cancer cells decreased significantly (P<0.05) in the P21 saRNA (3.10 +/- 0.13) and TIGIT siRNA (2.91 +/- 0.13) groups, compared with the blank control group (3.67 +/- 0.15); the experimental results showed that the healing rate of P21 saRNA group ((42.53 +/- 2.90)%) and TIGIT siRNA group ((36.23 +/- 3.43)%) were significantly lower than those of the blank control group ((76.47 +/- 3.64)%), P<0.05; Transwell assay showed that: P21 saRNA group (128.25 +/- 5.36), TIGIT siRNA group (119.50 +/- 8.79) were lower than the control group (186.5 +/- 8.56), P<0.05. And the invasion ability: P21 saRNA group (145.5 +/- 9.45), TIGIT siRNA group (112.25 +/- 5.63) were also significantly lower than the control group (202.50 +/- 10.12), P<0.05; apoptosis rate: P21 saRNA group ((11.74 +/- 2.47)%) and TIGIT siRNA group ((17.12 +/- 2.04)%) were significantly higher than the control group ((5.66 +/- 1.44)%), P<0.05.<bold>Conclusion</bold> The prepared AS1411-DNA/RNA-sxRNA hybrid vector can effectively target tumor cells, carry functional small RNAs into tumor cells, regulate the expression of target genes, and inhibit the proliferation, invasion and migration of tumor cells. The results provide an experimental basis for using DNA-RNA conjugated AS1411 aptamer as a hybrid carrier as a targeting tool to target and kill tumor cells expressing NCL protein on the surface.